MarkWide Research

Sale!

Hydroxychloroquine Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 172
Delivery Format: PDF + Excel

$2,950.00

Global hydroxychloroquine sales were valued at $1.9billion in 2019. By 2027, they are expected to reach $4.6 billion. From 2020 to 2027, the market is expected to grow at 7.9%.

Since the pandemic’s beginning, hydroxychloroquine has been used to treat COVID-19 victims. Although the demand has increased tenfolds, there has been controversy over the drug’s effectiveness in treatment.

Hydroxychloroquine, an anti-malarial medication, is used primarily to treat acute malaria attacks. It is also widely used as a disease-modifying antirheumatic drug (DMARD).

India is the world’s largest producer of hydroxychloroquine. India imposed a ban on exporting the drug due to its potential to treat COVID-19. This caused tension in diplomatic relations between the U.S. and India. Around 80 countries around the world are dependent on India’s medication.

Cadila Healthcare Ltd. and Hikma Pharmaceuticals PLC are the key players in the hydroxychloroquine market. They are constantly focusing their R&D efforts on the impact of multiple coatings on coronavirus.

Hydroxychloroquine market, by Product type.

The market can be divided into active pharmaceutical ingredients and tablets, depending on the product type. In 2019, the market was dominated by active pharmaceutical ingredients. The market’s top segment is active pharmaceutical ingredients in 2019. High demand for tablets also drives the hydroxychloroquine industry growth due to their cost-effectiveness, ease of use, and affordability.

Hydroxychloroquine market, by Distribution Channel.

The market can be divided into distribution channels online pharmacy, hospital pharmacy, specialty drug stores, retail pharmacy, and online pharmacy. Due to the continuous expansion of e-commerce, the online pharmacy segment will experience a significant growth rate over the forecast period. The market is expected to grow due to the increased penetration of e-commerce in the pharmaceutical sector during the epidemic, insufficient availability of medicine in hospitals pharmacy & retail pharmacies and time-saving features, as well as the ability of online platforms to deliver medicines at home during the lockdown.

Hydroxychloroquine market, by Disease.

The malaria segment will hold the largest market share for hydroxychloroquine in 2019. This is due to the alarming rise in malaria prevalence and the widespread use of hydroxychloroquine anti-malarial drugs. There are still malaria-endemic countries in Africa, which drives demand for the drug. HCQ is also included in the essential medicine list of the World Health Organization.

Hydroxychloroquine market, by Region.

In 2019, Asia-Pacific dominated the market in terms of Region. Asia-Pacific’s dominance is due to the presence and growth of market players such as India and China and the surge in medication demand due to high malaria rates in South East Asian countries.

Key Benefits for Stakeholders

  • This report includes an analysis of the market and forecasts for hydroxychloroquine, as well as current trends and future estimates.
  • This report focuses on the market’s key drivers, opportunities, and restraints and the impact analysis for the forecast period.
  • The Porter’s Five Forces analysis is used to determine the potential buyers and suppliers and the competitive environment in the hydroxychloroquine market for strategy building.
  • This report provides a comprehensive analysis of all factors that influence and inhibit the growth of the hydroxychloroquine industry.
  • The report provides qualitative data on hydroxychloroquine’s market dynamics, trends, and developments.
  • The market size for hydroxychloroquine is shown in terms of revenues.
  • This report offers extensive qualitative insight into the regions and segments with favorable market share.

Hydroxychloroquine Market  Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Key Market Segments

  • BY DISTRIBUTION CHANNEL
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online pharmacy
    • Specialty Drug Store
  • BY PRODUCT TYPE
    • Tablet
    • Active pharmaceutical ingredients
  • BY REGION
    • North America
      • US
      • Canada
      • Mexico
    • Europe
      • Germany
      • Italy
      • France
      • UK
      • Spain
      • Poland
      • Russia
      • The Netherlands
      • Norway
      • Czech Republic
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Indonesia
      • Malaysia
      • Thailand
      • Singapore
      • Australia & New Zealand
      • Rest of Asia Pacific
    • South America
      • Brazil
      • Argentina
      • Colombia
      • Rest of South America
    • The Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa
      • Northern Africa
      • Rest of MEA
  • BY DISEASES
    • Malaria
    • Rheumatoid Arthritis
    • Lupus Erythematosus
    • Coronavirus
    • Other

Key Market Participants

  • Cadila Healthcare Limited
  • Hikma Pharmaceuticals PLC
  • Zydus Group
  • IPCA Laboratories Ltd
  • Mylan N.V
  • Novartis International AG
  • Pfizer Inc
  • Sanofi S.A
  • Taj Pharma Group
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Limited

 

Table of Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top Player Positioning
3.2.3.Porter’s five forces analysis

3.3.Patent Analysis
3.4.Value chain analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in demand for HCQ as potential treatment source amidst pandemic
3.5.1.2.Increase in cases of malaria

3.5.2.Restraint

3.5.2.1.Several side-effects of the medicine
3.5.2.2.Ban from several countries owing to lacking study data
3.5.2.3.Ongoing research and positive results of other drugs for potential cure

3.5.3.Opportunity

3.5.3.1.Repurposing hydroxychloroquine as anti-cancer drug

3.6.Impact of CORONA (COVID 19) outbreak on global hydroxychloroquine market

CHAPTER 4:HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Tablet

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region

4.3.Active pharmaceutical ingredient

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region

CHAPTER 5:HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacy

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region

5.3.Retail pharmacy

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region

5.4.Online pharmacy

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region

5.5.Specialty drug store

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region

CHAPTER 6:HYDROXYCHLOROQUINE MARKET, BY DISEASES

6.1.Overview

6.1.1.Market size and forecast

6.2.Malaria

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region

6.3.Rheumatoid arthritis

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region

6.4.Lupus Erythematosus

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region

6.5.Coronavirus

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region

6.6.Others

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by region

CHAPTER 7:HYDROXYCHLOROQUINE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by product type
7.2.3.Market size and forecast, by distribution channel
7.2.4.Market size and forecast, by disease
7.2.5.Market share analysis, by country
7.2.6.U.S.

7.2.6.1.Market size and forecast, by product type
7.2.6.2.Market size and forecast, by distribution channel
7.2.6.3.Market size and forecast, by disease

7.2.7.Canada

7.2.7.1.Market size and forecast, by product type
7.2.7.2.Market size and forecast, by distribution channel
7.2.7.3.Market size and forecast, by disease

7.2.8.Mexico

7.2.8.1.Market size and forecast, by product type
7.2.8.2.Market size and forecast, by distribution channel
7.2.8.3.Market size and forecast, by disease

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by product type
7.3.3.Market size and forecast, by distribution channel
7.3.4.Market size and forecast, by disease
7.3.5.Market share analysis, by country
7.3.6.Germany

7.3.6.1.Market size and forecast, by product type
7.3.6.2.Market size and forecast, by distribution channel
7.3.6.3.Market size and forecast, by disease

7.3.7.France

7.3.7.1.Market size and forecast, by product type
7.3.7.2.Market size and forecast, by distribution channel
7.3.7.3.Market size and forecast, by disease

7.3.8.UK

7.3.8.1.Market size and forecast, by product type
7.3.8.2.Market size and forecast, by distribution channel
7.3.8.3.Market size and forecast, by disease

7.3.9.Italy

7.3.9.1.Market size and forecast, by product type
7.3.9.2.Market size and forecast, by distribution channel
7.3.9.3.Market size and forecast, by disease

7.3.10.Spain

7.3.10.1.Market size and forecast, by product type
7.3.10.2.Market size and forecast, by distribution channel
7.3.10.3.Market size and forecast, by disease

7.3.11.Rest of Europe

7.3.11.1.Market size and forecast, by product type
7.3.11.2.Market size and forecast, by distribution channel
7.3.11.3.Market size and forecast, by disease

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by product type
7.4.3.Market size and forecast, by distribution channel
7.4.4.Market size and forecast, by disease
7.4.5.Market share analysis, by country
7.4.6.China

7.4.6.1.Market size and forecast, by product type
7.4.6.2.Market size and forecast, by distribution channel
7.4.6.3.Market size and forecast, by disease

7.4.7.Japan

7.4.7.1.Market size and forecast, by product type
7.4.7.2.Market size and forecast, by distribution channel
7.4.7.3.Market size and forecast, by disease

7.4.8.India

7.4.8.1.Market size and forecast, by product type
7.4.8.2.Market size and forecast, by distribution channel
7.4.8.3.Market size and forecast, by disease

7.4.9.Australia

7.4.9.1.Market size and forecast, by product type
7.4.9.2.Market size and forecast, by distribution channel
7.4.9.3.Market size and forecast, by disease

7.4.10.South Korea

7.4.10.1.Market size and forecast, by product type
7.4.10.2.Market size and forecast, by distribution channel
7.4.10.3.Market size and forecast, by disease

7.4.11.Rest of Asia-Pacific

7.4.11.1.Market size and forecast, by product type
7.4.11.2.Market size and forecast, by distribution channel
7.4.11.3.Market size and forecast, by disease

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by product type
7.5.3.Market size and forecast, by distribution channel
7.5.4.Market size and forecast, by disease
7.5.5.Market share analysis, by country
7.5.6.Brazil

7.5.6.1.Market size and forecast, by product type
7.5.6.2.Market size and forecast, by distribution channel
7.5.6.3.Market size and forecast, by disease

7.5.7.Saudi Arabia

7.5.7.1.Market size and forecast, by product type
7.5.7.2.Market size and forecast, by distribution channel
7.5.7.3.Market size and forecast, by disease

7.5.8.South Africa

7.5.8.1.Market size and forecast, by product type
7.5.8.2.Market size and forecast, by distribution channel
7.5.8.3.Market size and forecast, by disease

7.5.9.Rest of LAMEA

7.5.9.1.Market size and forecast, by product type
7.5.9.2.Market size and forecast, by distribution channel
7.5.9.3.Market size and forecast, by disease

CHAPTER 8:COMPANY PROFILES:

8.1.Cadila Healthcare Limited

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Business performance

8.2.Hikma Pharmaceuticals PLC

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Business performance

8.3.IPCA Laboratories Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Product portfolio
8.3.4.Business performance
8.3.5.Key Developmental strategies

8.4.Mylan N.V.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key Developmental strategies

8.5.Novartis International AG

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Pfizer Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Business performance

8.7.Sanofi S.A.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Business performance

8.8.Taj Pharma Group

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Product portfolio

8.9.Teva Pharmaceutical Industries Ltd.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance

8.10.Torrent Pharmaceuticals Limited

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Business performance

LIST OF TABLES

TABLE 01.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 02.HYDROXYCHLOROQUINE MARKET FOR TABLET, BY REGION, 20192027 ($MILLION)
TABLE 03.HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 20192027 ($MILLION)
TABLE 04.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 05.HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY REGION, 20192027 ($MILLION)
TABLE 06.HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY REGION, 20192027 ($MILLION)
TABLE 07.HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY REGION, 20192027 ($MILLION)
TABLE 08.HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY REGION, 20192027 ($MILLION)
TABLE 09.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 20192027 ($MILLION)
TABLE 10.HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY REGION, 20192027 ($MILLION)
TABLE 11.HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 20192027 ($MILLION)
TABLE 12.HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY REGION, 20192027 ($MILLION)
TABLE 13.HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY REGION, 20192027 ($MILLION)
TABLE 14.HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY REGION, 20192027 ($MILLION)
TABLE 15.HYDROXYCHLOROQUINE MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 16.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 17.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 18.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 19.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 20192027 ($MILLION)
TABLE 20.U.S. HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 21.U.S. HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 22.U.S. HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 23.CANADA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 24.CANADA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 25.CANADA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 26.MEXICO HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 27.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 28.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 29.EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 30.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 31.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 32.EUROPE HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 20192027 ($MILLION)
TABLE 33.GERMANY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 34.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 35.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 36.FRANCE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 37.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 38.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 39.UK HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 40.UK HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 41.UK HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 42.ITALY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 43.ITALY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 44.ITALY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 45.SPAIN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 46.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 47.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 48.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 49.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 50.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 51.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 52.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 53.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 54.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 20192027 ($MILLION)
TABLE 55.CHINA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 56.CHINA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 57.CHINA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 58.JAPAN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 59.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 60.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 61.INDIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 62.INDIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 63.INDIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 64.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 65.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 66.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 67.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 68.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 69.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 73.LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 74.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 75.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 76.LAMEA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 20192027 ($MILLION)
TABLE 77.BRAZIL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 78.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 79.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 80.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 81.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 82.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 83.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 84.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 85.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 86.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILLION)
TABLE 87.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILLION)
TABLE 88.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 20192027 ($MILLION)
TABLE 89.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 90.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 91.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 92.HIKMA: COMPANY SNAPSHOT
TABLE 93.HIKMA: PRODUCT PORTFOLIO
TABLE 94.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 95.IPCA: COMPANY SNAPSHOT
TABLE 96.IPCA: PRODUCT PORTFOLIO
TABLE 97.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 98.IPCA: PRODUCT PORTFOLIO
TABLE 99.MYLAN: COMPANY SNAPSHOT
TABLE 100.MYLAN: PRODUCT PORTFOLIO
TABLE 101.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 102.MYLAN: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS: COMPANY SNAPSHOT
TABLE 104.NOVARTIS: OPERATING SEGMENTS
TABLE 105.NOVARTIS: PRODUCT PORTFOLIO
TABLE 106.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 107.PFIZER INC.: COMPANY SNAPSHOT
TABLE 108.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 109.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 110.SANOFI: COMPANY SNAPSHOT
TABLE 111.SANOFI: PRODUCT PORTFOLIO
TABLE 112.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 113.TAJ: COMPANY SNAPSHOT
TABLE 114.TAJ: PRODUCT PORTFOLIO
TABLE 115.TEVA: COMPANY SNAPSHOT
TABLE 116.TEVA: PRODUCT PORTFOLIO
TABLE 117.OVERALL FINANCIAL STATUS ($MILLION)
TABLE 118.TORRENT: COMPANY SNAPSHOT
TABLE 119.TORRENT: PRODUCT PORTFOLIO
TABLE 120.OVERALL FINANCIAL STATUS ($MILLION)

LIST OF FIGURES

FIGURE 01.KEY MARKET SEGMENTS
FIGURE 02.EXECUTIVE SUMMARY, BY SEGMENT
FIGURE 03.EXECUTIVE SUMMARY, BY COUNTRY
FIGURE 04.TOP INVESTMENT POCKETS
FIGURE 05.TOP PLAYER POSITIONING
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH THREAT OF NEW ENTRANTS
FIGURE 08.LOW THREAT OF SUBSTITUTES
FIGURE 09.HIGH INTENSITY OF RIVALRY
FIGURE 10.HIGH BARGAINING POWER OF BUYERS
FIGURE 11.PATENT ANALYSIS FOR HYDROXYCHLOROQUINE
FIGURE 12.VALUE CHAIN ANALYSIS FOR HYDROXYCHLOROQUINE MARKET
FIGURE 13.HYDROXYCHLOROQUINE MARKET DYNAMICS
FIGURE 14.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 20192027 ($MILILION)
FIGURE 15.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR TABLET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 20192027 ($MILILION)
FIGURE 18.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 20192027 ($MILILION)
FIGURE 23.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 28.U.S. HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 29.CANADA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 30.MEXICO HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 31.GERMANY HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 32.FRANCE HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 33.UK HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 34.ITALY HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 35.SPAIN HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 36.REST OF EUROPE HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 37.CHINA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 38.JAPAN HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 39.INDIA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 40.AUSTRALIA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 41.SOUTH KOREA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 42.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 43.BRAZIL HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 44.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 45.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 46.REST OF LAMEA HYDROXYCHLOROQUINE MARKET REVENUE, 20192027 ($MILLION)
FIGURE 47.ZYDUS CADILA: NET SALES, 20172019 ($MILLION)
FIGURE 48.ZYDUS CADILA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.ZYDUS CADILA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.HIKMA: NET SALES, 20172019 ($MILLION)
FIGURE 51.HIKMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 52.HIKMA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 53.IPCA: NET SALES, 20172019 ($MILLION)
FIGURE 54.IPCA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 55.IPCA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 56.MYLAN: NET SALES, 20172019 ($MILLION)
FIGURE 57.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 59.MYLAN: REVENUE SHARE BY COUNTRY OF SUNSIDIARIES, 2019 (%)
FIGURE 60.KOBE: NET SALES, 20172019 ($MILLION)
FIGURE 61.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 62.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 63.NOVARTIS: REVENUE SHARE BY DIVISION, 2019 (%)
FIGURE 64.PFIZER INC.: NET SALES, 20172019 ($MILLION)
FIGURE 65.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 66.PFIZER INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 67.SANOFI: NET SALES, 20172019 ($MILLION)
FIGURE 68.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 69.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 70.TEVA: NET SALES, 20172019 ($MILLION)
FIGURE 71.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 72.TORRENT: NET SALES, 20172019 ($MILLION)
FIGURE 73.TORRENT: REVENUE SHARE BY REGION, 2019 (%)

Segmentation

  • BY DISTRIBUTION CHANNEL
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online pharmacy
    • Specialty Drug Store
  • BY PRODUCT TYPE
    • Tablet
    • Active pharmaceutical ingredients

Major Companies

  • Cadila Healthcare Limited
  • Hikma Pharmaceuticals PLC
  • Zydus Group
  • IPCA Laboratories Ltd
  • Mylan N.V
  • Novartis International AG
  • Pfizer Inc
  • Sanofi S.A
  • Taj Pharma Group
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Limited

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF